Cargando…
Targeting of SLC25A22 boosts the immunotherapeutic response in KRAS-mutant colorectal cancer
KRAS is an important tumor intrinsic factor driving immune suppression in colorectal cancer (CRC). In this study, we demonstrate that SLC25A22 underlies mutant KRAS-induced immune suppression in CRC. In immunocompetent male mice and humanized male mice models, SLC25A22 knockout inhibits KRAS-mutant...
Autores principales: | Zhou, Qiming, Peng, Yao, Ji, Fenfen, Chen, Huarong, Kang, Wei, Chan, Lam-Shing, Gou, Hongyan, Lin, Yufeng, Huang, Pingmei, Chen, Danyu, Wei, Qinyao, Su, Hao, Liang, Cong, Zhang, Xiang, Yu, Jun, Wong, Chi Chun |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10403583/ https://www.ncbi.nlm.nih.gov/pubmed/37542037 http://dx.doi.org/10.1038/s41467-023-39571-6 |
Ejemplares similares
-
The cholesterol uptake regulator PCSK9 promotes and is a therapeutic target in APC/KRAS-mutant colorectal cancer
por: Wong, Chi Chun, et al.
Publicado: (2022) -
Targeting m(6)A reader YTHDF1 augments antitumour immunity and boosts anti-PD-1 efficacy in colorectal cancer
por: Bao, Yi, et al.
Publicado: (2023) -
Prognostic and Immunotherapeutic Roles of KRAS in Pan-Cancer
por: Yang, Kaixin, et al.
Publicado: (2022) -
LC-MS-based metabolomics revealed SLC25A22 as an essential regulator of aspartate-derived amino acids and polyamines in KRAS-mutant colorectal cancer
por: Li, Xiaona, et al.
Publicado: (2017) -
Small Molecule KRAS Agonist for Mutant KRAS Cancer Therapy
por: Xu, Ke, et al.
Publicado: (2019)